IMMUNOCOMPROMISED PATIENTS
Forecast sales for the immuno-stimulants market are estimated to reach $17.6 billion.
The Cancer Market Outlook: Competitive landscape, pipeline analysis and growth opportunitiesPulmotect announces FDA approval for two clinical trials to prevent and treat COVID-19
Learn MorePULMOTECT, INC. is a bio-pharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.
COPD EXACERBATIONS
COPD, which includes chronic bronchitis and emphysema, affects more than 24 million Americans and is the third leading cause of death in the U.S.
Centers for Disease Control
EPIDEMIC AND EMERGING PATHOGENS
More than 2 billion people worldwide could be impacted by a pandemic. Despite remarkable advances in medical research and treatments during the 20th century, infectious diseases remain among the leading causes of death worldwide.
National Institute of Allergy and Infectious DiseaseOur Product
Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection that lasts for days against all major classes of pathogens.
Our Research
Two previously completed phase I clinical trials demonstrated that PUL-042 was well tolerated in healthy individuals. A Phase IIa viral challenge study is ongoing and Phase II studies are being planned to assess the effectiveness of PUL-042 in preventing respiratory tract complications in immunocompromised cancer patients.
The Market
Pulmotect’s initial focus is on the reduction of complications in cancer patients undergoing chemotherapy. Additional potential indications include reductions of COPD exacerbations, which are characterized by an acute worsening of symptoms, mostly precipitated by a bacterial or viral infection. Further unmet medical needs include treatment of viral infections, such as influenza.